ALPS Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,569
| Closed | -$330K | – | 1014 |
|
|
2023
Q2 | $330K | Buy |
1,569
+10
| +0.6% | +$1.99K | ﹤0.01% | 791 |
|
|
2023
Q1 | $315K | Buy |
1,559
+84
| +6% | +$19K | ﹤0.01% | 827 |
|
|
2022
Q4 | $321K | Sell |
1,475
-9
| -0.6% | -$1.97K | ﹤0.01% | 818 |
|
|
2022
Q3 | $292K | Buy |
+1,484
| New | +$320K | ﹤0.01% | 842 |
|
|
2022
Q1 | – | Sell |
-851
| Closed | -$321K | – | 862 |
|
|
2021
Q4 | $321K | Buy |
851
+18
| +2% | +$6.99K | ﹤0.01% | 817 |
|
|
2021
Q3 | $344K | Sell |
833
-341
| -29% | -$142K | ﹤0.01% | 765 |
|
|
2021
Q2 | $434K | Hold |
1,174
| – | – | ﹤0.01% | 546 |
|
|
2021
Q1 | $340K | Buy |
1,174
+11
| +0.9% | +$3.06K | ﹤0.01% | 646 |
|
|
2020
Q4 | $291K | Sell |
1,163
-35
| -3% | -$8.34K | ﹤0.01% | 733 |
|
|
2020
Q3 | $271K | Sell |
1,198
-573
| -32% | -$119K | ﹤0.01% | 618 |
|
|
2020
Q2 | $309K | Sell |
1,771
-199
| -10% | -$31.8K | ﹤0.01% | 552 |
|
|
2020
Q1 | $249K | Buy |
+1,970
| New | +$295K | ﹤0.01% | 572 |
|
|
2019
Q3 | – | Sell |
-2,724
| Closed | -$387K | – | 857 |
|
|
2019
Q2 | $387K | Sell |
2,724
-144
| -5% | -$19.5K | ﹤0.01% | 667 |
|
|
2019
Q1 | $417K | Buy |
+2,868
| New | +$377K | ﹤0.01% | 607 |
|
|
2018
Q1 | – | Sell |
-4,304
| Closed | -$471K | – | 896 |
|
|
2017
Q4 | $471K | Hold |
4,304
| – | – | ﹤0.01% | 611 |
|
|
2017
Q3 | $465K | Sell |
4,304
-1,046
| -20% | -$107K | ﹤0.01% | 641 |
|
|
2017
Q2 | $541K | Buy |
5,350
+14
| +0.3% | +$1.29K | ﹤0.01% | 430 |
|
|
2017
Q1 | $480K | Buy |
+5,336
| New | +$453K | ﹤0.01% | 517 |
|
|
2016
Q3 | – | Sell |
-5,597
| Closed | -$461K | – | 686 |
|
|
2016
Q2 | $461K | Sell |
5,597
-408
| -7% | -$33.6K | ﹤0.01% | 313 |
|
|
2016
Q1 | $456K | Sell |
6,005
-1,040
| -15% | -$77K | ﹤0.01% | 317 |
|
|
2015
Q4 | $566K | Hold |
7,045
| – | – | 0.01% | 303 |
|
|
2015
Q3 | $448K | Buy |
7,045
+597
| +9% | +$42.9K | ﹤0.01% | 588 |
|
|
2015
Q2 | $454K | Buy |
6,448
+100
| +2% | +$7.4K | ﹤0.01% | 593 |
|
|
2015
Q1 | $503K | Sell |
6,348
-2,298
| -27% | -$170K | ﹤0.01% | 571 |
|
|
2014
Q4 | $550K | Sell |
8,646
-1,254
| -13% | -$78.6K | ﹤0.01% | 377 |
|
|
2014
Q3 | $591K | Buy |
+9,900
| New | +$566K | ﹤0.01% | 316 |
|
Other funds holding CRL
AI
ALPS Advisors's CRL Position: Q3 2023 in Review
ALPS Advisors sold out of Charles River Laboratories (CRL) in Q3 2023, closing a stake of 1,569 shares — an estimated $330K sold.
ALPS Advisors first reported a position in CRL in Q3 2014 and held it in 26 quarters. The position peaked at $591K in Q3 2014. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.
- ALPS Advisors reported no remaining Charles River Laboratories position as of Q3 2023 after selling out during the quarter.
- ALPS Advisors sold 1,569 Charles River Laboratories shares in Q3 2023, an estimated $330K.
- ALPS Advisors first reported a position in Charles River Laboratories in Q3 2014 and held it in 26 quarters.
- ALPS Advisors's Charles River Laboratories position peaked at $591K in Q3 2014.
- 621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.
Based on ALPS Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.